From the perspective of reducing oncogenesis, inhibiting Gadd45β as a method for preventing HCC oncogenesis has limited prospects and acceptance compared with post‐tumour intervention treatment (Table 2). Here, GADD45B is linked to hepatocellular carcinoma.